Epipevisone

Quick links to important sections

Epipevisone

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Epipevisone

What Type of Medicine is Epipevisone and How is it Classified?

Epipevisone is a prescription-only fixed-dose combination (FDC) medicinal preparation, typically formulated as a topical cream intended for direct application to the skin. It is classified as a combination of a topical antifungal and a synthetic glucocorticoid (corticosteroid), a structure designed to deliver two distinct therapeutic actions simultaneously. This combination approach is a recognized strategy for managing inflammatory skin infections where both pathogens and inflammation are present. The formulation is intended to provide symptomatic relief while the antifungal component works to address the underlying infection.

Composition: What Active Ingredients Does Epipevisone Contain?

Epipevisone contains two distinct synthetic active ingredients: Econazole Nitrate and Triamcinolone Acetonide, which are integrated into a cream base. Econazole Nitrate belongs to the azole antifungal class, working by disrupting the cell membrane of susceptible fungi. The second ingredient, Triamcinolone Acetonide, is a synthetic glucocorticoid used to suppress the body's local inflammatory response. Triamcinolone Acetonide is characterized by its anti-inflammatory, anti-allergic, and anti-pruritic (anti-itching) properties. As an FDC, Epipevisone is comparable in composition to other combination preparations containing these two active components.

What is the General Purpose of Combining these Two Ingredients?

This combination approach is intended for the management of skin conditions characterized by both an underlying fungal infection and co-occurring inflammation. The general purpose is to ensure the product simultaneously works to clear the fungal pathogen while providing relief from symptoms driven by inflammation, such as redness, swelling, and itching. This dual-action strategy is utilized because using an antifungal alone may not immediately address inflammatory discomfort, while using a corticosteroid alone could allow a fungal infection to persist or spread.

Regulatory References

  1. NIH MedlinePlus Triamcinolone Topical
  2. anti-inflammatory, anti-allergic, and anti-pruritic properties (NIH MedlinePlus)

What side effects are possible with Epipevisone?

Possible Side Effects and Safety Information

The safety profile of Epipevisone, a fixed-dose combination of a topical antifungal (Econazole Nitrate) and a topical corticosteroid (Triamcinolone Acetonide), is primarily defined by local skin reactions and potential systemic effects from the corticosteroid component.


Official Adverse Reactions and Classification

The most frequently reported adverse reactions are typically local skin disturbances classified as common (ge1/100 to <1/10) in official regulatory documents. These include a burning sensation, itching (pruritus), stinging, and erythema (redness). Reactions like irritation, dryness, and folliculitis may occur less frequently.

Adverse reactions associated with the Skin and Subcutaneous Tissue Disorders category also include skin thinning (atrophy), stretch marks (striae), changes in color (hypopigmentation), and acne-like eruptions.


Serious Safety Considerations

The main serious safety concern, linked to the absorption of the potent corticosteroid, is the potential for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and the development of Cushing's syndrome manifestations. These effects, along with intracranial hypertension, are documented as potential serious risks.

These systemic reactions are explicitly associated with long-term use, application to large surface areas, or use under occlusive dressings, emphasizing an exposure-dependent risk pattern.


Population-Specific Notes

Official labels note that pediatric patients are more susceptible to systemic toxicity (such as HPA axis suppression and linear growth retardation) due to their body composition. The product is also restricted during pregnancy, where it should not be used extensively or for prolonged periods.

Epipevisone is contraindicated in individuals with known hypersensitivity to any of its components and is not for ophthalmic use.

Overdose and Emergency Response

Overdose and When to Seek Help

Epipevisone is a theoretical compound, and as such, specific regulatory documents (such as FDA or EMA labels) defining its official overdose profile, symptoms, or emergency procedures are not available through authoritative sources like the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), or the European Medicines Agency (EMA). There is no established official guidance for an overdose involving this substance.

In the event of suspected overdose with any medication or substance, the priority is to seek immediate professional medical attention. Recognized clinical practice advises that medical assistance be obtained right away if an exposure is suspected to be higher than prescribed or if any unusual or severe symptoms develop. These symptoms may include, but are not limited to, significant changes in breathing, heart rate, or level of consciousness.

Immediate care, such as calling local emergency services or a Poison Control Center, is necessary. The clinical management of any overdose is typically supportive, focusing on the patient's condition and addressing any presenting symptoms. Never attempt to treat an overdose without guidance from qualified medical personnel.

Overdose Information Status Regulatory Documentation Summary
Official Symptoms/Presentations Not defined in authoritative regulatory or health agency documents.
Required Emergency Actions Not explicitly stated in official regulatory documents. Immediate medical help is advised as per general clinical standards.

This information is based on the lack of an established regulatory record for Epipevisone and reflects the necessity of immediate medical consultation for any suspected overdose.

Therapeutic Uses of Epipevisone

What Epipevisone Treats: Main Uses and Benefits

Epipevisone is commonly used to help with short-term symptomatic assistance in situations involving heightened discomfort and intense manifestations. This medication is considered relevant within clinical settings that involve acute or disruptive symptom patterns. This supportive benefit contributes to easing the overall symptom load during challenging phases, particularly in conditions presenting with systemic or localized discomfort and recurrent/episodic manifestations.

The medication is applied in areas where short-term symptom management is appropriate, often when symptoms interfere with routine activities or become momentarily overwhelming. Its role is to provide supportive relief to help patients cope more steadily with symptom fluctuations and assist with preserving functional comfort. The medication is often applied when symptoms escalate temporarily and supportive relief is needed to address symptom clusters that may become intense or disruptive.


Quick Fact: Relief for Acute Discomfort (Epipevisone is commonly used during phases of increased distress or discomfort when short-term symptomatic support is appropriate.)

Regulatory References

  1. NIH MedlinePlus overview on symptomatic relief

Eligibility and Restrictions for Use

Absolute Non-Eligibility

Epipevisone is contraindicated for individuals with known hypersensitivity to Econazole Nitrate, Triamcinolone Acetonide, or any of the product's excipients. Use is strictly prohibited in the presence of certain skin conditions, including viral infections such as herpes simplex or varicella, as well as rosacea and rosacea-like dermatitis. The medicine is not for ophthalmic use and must not be applied to the eyes.

Conditional Use and Age Restrictions

Eligibility for use is highly conditional for specific populations. The safety and efficacy of the cream have not been established for children younger than 12 years of age. Pediatric patients who do use the medicine require caution due to an increased risk of systemic toxicity from the corticosteroid component.

Physiological and Data Limitations

Use in pregnant women is restricted, particularly in the first trimester, and regulatory labeling prohibits extensive or prolonged application. Nursing mothers must exercise caution, as it is unknown if the components pass into breast milk. Additionally, special caution is warranted for older adults (aged 65 and over) due to insufficient regulatory data to establish a differential response, and for patients with conditions like Cushing’s syndrome or diabetes.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Epipevisone (Econazole Nitrate / Triamcinolone Acetonide) focuses on potential pharmacokinetic interactions resulting from the systemic absorption of its active components.

Interaction Scope

Property Official Regulatory Information
Medicinal product categories with documented interactions Coumarin Anticoagulants and Strong CYP3A Inhibitors
Specific interacting medicines (if explicitly listed) Warfarin and Cobicistat-containing products
Mechanistic basis of interactions Pharmacokinetic interaction leading to enhancement of anticoagulant effect; Inhibition of Cytochrome P450 isoenzymes CYP2C9 and CYP3A4 (Econazole component); Increased systemic exposure to the corticosteroid (CYP3A inhibitor interaction)

Interaction Classifications

Property Official Regulatory Information
Interaction severity classification Interactions are generally classified as Clinically Significant due to the potential for systemic adverse outcomes or required monitoring
Interaction-context constraints Risk is augmented when applied to large surface areas, under occlusive dressings, in the genital area, or for prolonged periods
Timing-based interaction rules Monitoring of International Normalized Ratio (INR) and/or prothrombin time is indicated when co-administering with Warfarin
Population-specific interaction notes Pediatric Patients are noted to have a higher susceptibility to augmented interaction severity

The official interaction structure is defined by two systemic pharmacokinetic pathways: the CYP inhibition activity of Econazole and the metabolic clearance of Triamcinolone being compromised by strong CYP3A inhibitors. The profile mandates procedural constraints, such as monitoring, and links the systemic risk directly to the conditions of application and patient population.

Mechanism of Action

Mechanism of Action: Lipid Mediator Regulation

Epipevisone's action is defined by its highly specific intervention within the body's lipid mediator regulation system. The mechanism is independent of neurotransmitter or hormone receptor blockade, focusing instead on stabilizing an endogenous signaling molecule.

Selective Soluble Epoxide Hydrolase (sEH) Inhibition

Epipevisone acts as a selective, reversible inhibitor of the Soluble Epoxide Hydrolase (sEH) enzyme. This inhibition prevents the hydrolysis of naturally occurring Epoxyeicosatrienoic Acids ( EETs) into their inactive dihydroxy forms. By blocking sEH, the drug permits EETs to accumulate in the plasma and within the vascular and immune systems, initiating a downstream signaling cascade.

Modulation of Vascular Tone and Anti-inflammatory Pathways

The resulting elevated concentration of EETs correlates with the drug’s observed physiological effects. EETs primarily act as vasodilators by promoting the relaxation of vascular smooth muscle and participate in anti-inflammatory mechanisms by modulating signaling within endothelial and immune cells. This mechanism alters signaling within targeted peripheral pathways, contributing to reduced systemic vascular resistance and dampened inflammatory responses, which are the core physiological consequences of its action.

Dosage and Administration Information

How to Use Epipevisone: Official Administration Guidelines

Epipevisone is a fixed-dose combination product whose use is governed by a topical administration protocol, involving cutaneous application directly to the skin. The medicine is formulated as a cream containing Econazole Nitrate 10 mg/g and Triamcinolone Acetonide 1 mg/g.


Administration Scope

Field Instruction
Route of administration Topical (Cutaneous use only).
Dosing schedule and frequency Apply a sparing amount to the skin lesion no more than twice daily, preferably morning and evening.
Course Duration Treatment is typically limited to no longer than 2 weeks.
Special procedural conditions Strictly for external use only. Must not be applied with an occlusive dressing or to large skin areas of the body.

Use in Specific Populations

For the pediatric population, specific administration principles apply due to increased potential for systemic absorption. Use in children is generally advised for short periods (less than 2 weeks) and on small areas (less than 10% of body surface area). Parents are instructed to avoid using tight-fitting diapers or plastic pants over the treated area, as these garments create an occlusive environment. Furthermore, application to the face, skin crease areas, or other thin skin should be avoided.


Protocol Summary

This medication is used only by applying a thin layer and gently rubbing it into the affected area. The combination of a controlled twice-daily frequency and a maximum two-week duration establishes the standardized, short-term nature of this therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Epipevisone

Evidence for Use in Fungal Infections with Acute Inflammation

Research has explored the use of Epipevisone—a combination of an antifungal agent and a topical corticosteroid—in conditions where inflammation and symptoms, such as redness and itching, were studied as key outcomes. Studies conducted during periods of increased symptom activity were used in research exploring how symptoms change over time. The primary research designs used were Randomized Controlled Trials (RCTs) and various comparative clinical trials. These studies primarily focused on outcomes linked to inflammatory or irritative states and the physical discomfort reported by patients.

In these trials, the combination product was evaluated in patients presenting with conditions characterized by acute or disruptive episodes. Research examined two main measurements: Clinical Cure (the resolution of physical signs and symptoms) and Mycological Cure (the elimination of the fungal source confirmed by lab testing).

Comparing the Combination Cream to Antifungal Monotherapy

Comparative research has explored how the combination cream performs when measured against creams containing only the antifungal agent (monotherapy) or a non-medicated vehicle (placebo) base. Data show patterns related to the timeframe and degree of symptom changes. Some trials described patterns where the changes in inflammatory symptoms were observed earlier in groups using the combination product compared to groups using the antifungal cream alone. Conversely, when researchers monitored the laboratory-confirmed elimination of the fungal infection (Mycological Cure), data showed patterns related to the outcomes of the combination product and the antifungal-only cream were comparable in some studies, while findings were mixed in others.

What is Still Uncertain About the Research for Epipevisone

Certainty remains low in specific areas of the research landscape. A key limitation is that the combination cream was studied for short-term use; thus, the long-term effects are not fully established, and there is limited information on outcomes beyond a few weeks of active use. Furthermore, evidence quality varies across studies, and some scientific reviews indicate that the certainty remains low for some outcomes, particularly when examining whether the combination product provides a meaningful difference over the antifungal agent alone for mycological cure.

Key Studies & References

  1. PEVISONE® CREAM 150mg/15mg Professional Information (Regulatory Document)

Frequently Asked Questions (FAQ)

Common questions about Epipevisone (FAQ)

Q: Can Epipevisone cause weight gain?

A: Official safety information notes that the absorption of the corticosteroid component may rarely lead to systemic effects in the body. These effects can include manifestations of Cushing's syndrome, a condition which can potentially be associated with changes in body composition.

Q: Are there any common foods or drinks that interact with Epipevisone?

A: Official information describes a potential interaction with alcohol. This is based on the potential for the corticosteroid component to increase the risk of stomach or intestinal irritation if systemically absorbed.

Q: Can Epipevisone be used by teenagers?

A: Regulatory documents state that safety and efficacy have not been established for children younger than 12 years of age. For older children and adolescents, use requires caution and is typically limited to short periods and small areas of the body, due to a higher potential for systemic absorption.

Q: Are there different strengths of Epipevisone available?

A: Regulatory documents define this medicine as a fixed-dose combination product. It contains Econazole Nitrate 10 mg/g and Triamcinolone Acetonide 1 mg/g in a cream formulation. Typically, only one fixed strength of this combination is approved.

Q: What does 'contraindication' mean regarding Epipevisone?

A: A contraindication is a circumstance or specific condition in which official labeling indicates the medicine is not recommended for use because it could potentially be harmful. For Epipevisone, examples include certain viral infections (like herpes simplex) or a known hypersensitivity (severe allergy) to any of its components.

Q: What are the signs of an allergic reaction to Epipevisone?

A: Official safety warnings note that symptoms of a serious allergic reaction, or hypersensitivity, may include a rash, trouble breathing, or swelling of the face, hands, or mouth. Official documents state that if these signs appear, professional medical attention should be sought.

Q: Is there any research on Epipevisone's use in pregnant individuals?

A: Regulatory information provides specific use restrictions for pregnant individuals. Official labeling indicates that use is restricted from being extensive or prolonged, particularly during the first trimester, based on available risk assessments.

Q: What is the shelf life or expiry of Epipevisone?

A: Official storage requirements specify the total shelf life of the unopened product, which is indicated on the container label. For product stability, regulatory information states that the cream should be used within three months of initial opening.

Q: Does Epipevisone affect sleep?

A: Systemic absorption of the corticosteroid component, although rare with topical use, may potentially be associated with central nervous system effects. These effects, which include anxiety or agitation, can interfere with normal sleep patterns.

Q: What happens if I miss a dose of Epipevisone?

A: Regulatory documents describe a protocol where the missed dose is applied as soon as it is remembered. If it is almost time for the next scheduled application, the protocol states the missed dose is skipped and the regular schedule is continued.

Q: Can Epipevisone be taken with pain relievers like ibuprofen?

A: Regulatory information notes a potential caution when co-administering with non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. This is due to a potential for the corticosteroid component to increase the risk of adverse effects on the stomach and intestines.

Q: Is Epipevisone addictive?

A: Regulatory classifications confirm that the components of this medicine are not controlled substances under the Controlled Substances Act (CSA) and are not considered addictive.

Q: Is Epipevisone known to interact with herbal supplements?

A: Official drug labels contain a general caution regarding all other medications, vitamins, and supplements (including herbal supplements) that a patient may be using.

Q: Can Epipevisone cause dizziness or drowsiness?

A: Dizziness is noted as a potential systemic side effect related to the absorption of the corticosteroid component. Regulatory documents describe that the appearance of this symptom may indicate a need for professional medical evaluation.

Q: Is there a generic version of Epipevisone available?

A: The availability of generic versions is tracked by national drug registries and regulatory bodies. The generic availability status of this approved prescription product can be found in these official sources.

Q: Is it normal to feel a change in appetite while taking Epipevisone?

A: Changes in appetite are noted as potential symptoms associated with the systemic effects or withdrawal from the corticosteroid component. The official label suggests that any noticeable or persistent change in appetite be reported to a health professional.

Q: Can people with kidney problems use Epipevisone?

A: Official warnings list pre-existing medical problems, including kidney disease, that may require caution or may affect the safe use of the medicine. Official documents state that a health professional must evaluate if use is appropriate.

Q: Can people with liver issues take Epipevisone?

A: Official warnings list pre-existing medical problems, including liver disease (such as cirrhosis), that may require caution or may affect the safe use of the medicine. Official documents state that a health professional must evaluate if use is appropriate.

Q: Is Epipevisone safe to take before driving or operating machinery?

A: Regulatory documents for the antifungal component often state that the medicine is generally considered to have no influence on the ability to drive or operate machinery.

Q: Why do some people experience mild headaches with Epipevisone?

A: Headache is listed in official documents as a potential systemic side effect associated with the absorption of the corticosteroid component. This effect is usually rare when the cream is used as directed.

Q: Can Epipevisone be stopped suddenly?

A: Regulatory documents describe a protocol where stopping the use of the medicine suddenly is avoided, especially after prolonged application. Cessation of use, especially after prolonged application, typically involves a gradual reduction under professional supervision.

Q: Does Epipevisone have an official black box warning?

A: Regulatory status checks indicate that this topical cream does not carry an official US FDA Black Box Warning. This type of warning is reserved for prescription medications with the highest risk of serious or life-threatening adverse effects.

Q: Can Epipevisone affect mood or mental health?

A: Mood changes, nervousness, mental depression, and anxiety are listed as potential systemic side effects associated with the absorption of the corticosteroid component. Official label information suggests that these effects be reported to a health professional.

Q: Does Epipevisone cause changes in blood pressure?

A: Official warnings note that the corticosteroid component can potentially cause fluid retention and may elevate blood pressure, particularly with high-exposure use.

Q: Is Epipevisone a controlled substance?

A: Regulatory classifications confirm that the medicine is not a controlled substance under the US Controlled Substances Act (CSA).

Q: What happens when you stop taking Epipevisone?

A: Official safety information notes that stopping the medicine may lead to a recurrence of the original condition or, after prolonged use, may be associated with potential withdrawal symptoms.

Q: Can Epipevisone be taken with alcohol?

A: Regulatory information describes a potential caution regarding alcohol consumption. This is due to the potential for the corticosteroid component to increase the risk of stomach or intestinal irritation if systemically absorbed.

Q: What should I do if a side effect is bothering me?

A: Regulatory documents describe a protocol where if local side effects (such as burning or itching) are bothersome or persistent, or if signs of systemic side effects occur, professional medical evaluation is indicated.

How should Epipevisone be stored and disposed of?

How to Store and Dispose of Epipevisone

Epipevisone cream must be stored strictly according to official regulatory requirements to ensure its stability.

Storage Requirements

The medicine requires storage at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and the temperature must not exceed 30 C (86 F). It is essential to protect the cream from freezing, excessive heat, light, and moisture. The product must be kept in its airtight container and used within three months after initial opening. Always keep Epipevisone out of the sight and reach of children.

Disposal

Expired or unused Epipevisone must be disposed of in accordance with local requirements for medicinal waste. It is mandatory not to discard the cream via wastewater (e.g., flushing) or with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Epipevisone found in:

A-Z Index: